Physician profile
Jack L Johnson
NPI 1801859996
$728.90
in general payments reported to CMS, 2019-2025
14 companies · $83.89 in 2025
The $83.89 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59.72 · 2023: $366 · 2024: $219 · 2025: $83.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $574 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $574.19 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $150.85 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Abbott Laboratories | $110.61 | 2023-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Astellas Pharma US INC | $110.59 | 2023 | Veozah |
| Abbvie INC. | $79.99 | 2019-2025 | |
| Lilly USA, LLC | $49.45 | 2024-2025 | Mounjaro, Zepbound |
| Dynavax Technologies Corporation | $37.68 | 2023-2024 | Heplisav-B |
| Upsher-Smith Laboratories LLC | $36.13 | 2019 | |
| Exact Sciences Corporation | $32.97 | 2023-2024 | Cologuard Collection Kit |
| Pfizer INC. | $23.81 | 2023 | |
| Sanofi-Aventis U.S. LLC | $23.05 | 2024 | |
| Dexcom, INC. | $21.82 | 2023 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $20.45 | 2025 | Capvaxive, Gardasil 9 |
| Tris Pharma INC | $18.09 | 2024 | Dyanavel Xr |
| Astrazeneca Pharmaceuticals LP | $13.41 | 2023 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.